Skip to main content
Medivir logo

Medivir — Investor Relations & Filings

Ticker · MVIR ISIN · SE0020181014 LEI · 549300VWDGUX0WMJ1T79 ST Manufacturing
Open in API
Filings indexed 965 across all filing types
Latest filing 2017-07-25 Interim / Quarterly Rep…
Country SE Sweden
Listing ST MVIR

About Medivir

https://www.medivir.com/

Medivir is a pharmaceutical company specializing in the discovery and clinical development of innovative drugs for cancer. The company focuses on oncology areas with high unmet medical needs, aiming to provide transformative treatments for patients with limited therapeutic options. Its research and development strategy is based on extensive expertise in drug design, particularly targeting enzymes such as proteases and polymerases, and includes the use of a proprietary prodrug platform. Medivir actively pursues collaborations with academic and industrial partners to advance its pipeline from research through to commercialization.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2017
Interim / Quarterly Report Classification · 100% confidence The document is titled 'INTERIM REPORT JANUARY – JUNE 2017' and contains detailed financial summaries, including net turnover, EBITDA, earnings per share, and cash flow for both the second quarter and the six-month period. It also includes management commentary, project pipelines, and operational updates. As it provides comprehensive financial data for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. H1 2017
2017-07-25 English
Rekryteringen till fortsättningsstudien inom artrosprogrammet har slutförts och dataövervakningskommittén rekommenderar fortsättning av studien
Regulatory Filings Classification · 95% confidence The document is a press release from Medivir AB announcing progress in a clinical trial (Phase IIa study for osteoarthritis). It details recruitment completion, a recommendation from the Data Monitoring Committee to continue the study, expected data release timelines (Q3 2017, H1 2018), and quotes from the CEO. The text concludes with a statement that the information is required to be made public under EU Market Abuse Regulation and specifies the release time (June 9, 2017). This structure—a brief announcement of material, non-financial operational/clinical progress, often released outside of standard quarterly reporting cycles—is characteristic of a general regulatory announcement or press release that doesn't fit the specific financial report categories (10-K, IR, ER). Since it is a formal announcement required under market rules but doesn't fit ER (Earnings Release), IR (Interim Report), or CAP (Financing Update), the most appropriate general category for mandatory regulatory disclosures that don't fit elsewhere is Regulatory Filings (RNS). The document length (4526 chars) is short enough that it is not the full underlying report, but an announcement about the study's status.
2017-06-09 Swedish
Enrolment completed in the MIV-711 osteoarthritis extension study and data monitoring committee recommendation to “Go Ahead”
Regulatory Filings Classification · 95% confidence The document is a press release from Medivir AB announcing clinical trial progress (enrollment completion and DMC recommendation) for their drug MIV-711. It provides updates on expected data reporting timelines (Q3 2017, H1 2018) and discusses the market potential. Crucially, the final paragraph states: "This information is information that Medivir AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication... on 9 June 2017." This structure—a brief announcement of material, non-financial, or operational news that is legally required to be disclosed—fits best under the general 'Regulatory Filings' category (RNS) as it is not a specific financial report (10-K, IR, ER), a management/board change (MANG), or a specific legal/shareholder event. It is a general regulatory disclosure.
2017-06-09 English
Beslut vid årsstämma i Medivir den 3 maj 2017
AGM Information Classification · 99% confidence The document title is "Beslut vid årsstämma i Medivir den 3 maj 2017" which translates to "Decisions at the Annual General Meeting in Medivir on May 3, 2017". The content details decisions made regarding the election of the board of directors, remuneration, guidelines for executive compensation, shareholder voting procedures (valberedning), authorization for share issuance (emissionsbemyndigande), and the approval of the 2016 financial statements and discharge of liability. These topics are central to the proceedings and outcomes of an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM-R (AGM Information).
2017-05-03 Swedish
Resolutions at the Annual General Meeting in Medivir on 3 May 2017
AGM Information Classification · 99% confidence The document explicitly details the 'Resolutions at the Annual General Meeting in Medivir on 3 May 2017'. It covers the election of the board, remuneration decisions, approval of financial statements, and authorizations passed during this meeting. This content is characteristic of the official minutes or summary of an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM-R.
2017-05-03 English
Interim / Quarterly Report 2017
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for Medivir AB covering the period January to March 2017. It contains comprehensive financial summaries, management commentary, project status updates, and financial tables. It is not an announcement of a report, but the report itself, and it covers a period shorter than a full fiscal year. Q1 2017
2017-04-28 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.